Journal
CANCER CELL
Volume 16, Issue 6, Pages 498-509Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2009.10.014
Keywords
-
Categories
Funding
- Ohio State University Targeted Investment
- Associazione Italiana Ricerca sul Cancro
- NATIONAL CANCER INSTITUTE [R01CA135030] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Lung and liver cancers are among the most deadly types of cancer. Despite improvements in treatment over the past few decades, patient survival remains poor, underlining the need for development of targeted therapies. MicroRNAs represent a class of small RNAs frequently deregulated in human malignancies. We now report that miR-221&222 are overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells. We show that miR-221&222, by targeting PTEN and TIMP3 tumor suppressors, induce TRAIL resistance and enhance cellular migration through the activation of the AKT pathway and metallopeptidases. Finally, we demonstrate that the MET oncogene is involved in miR-221&222 activation through the c-Jun transcription factor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available